SEC Form 4 · accession 0001209191-18-007410
bluebird bio, Inc. · BLUE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Nick Leschly
Officer — President and CEO · Director
Period of report
Feb 1, 2018
Accepted (ET)
Feb 5, 2018 · 4:04 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001293971
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Feb 1, 2018 | A | 30,000 | $0.00 | A | 200,577 | D | |
| Common Stock | holding | — | — | — | 17,186 | I | Nick Leschly 2001 Trust |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F3 | $205.25 | Feb 1, 2018 | A | 120,000 | A | — | Feb 1, 2028 | Common Stock | 120,000 | 120,000 | D |
Explanation of responses
- F1Restricted stock units for common stock vest over a four-year period at a rate of 25% on 01/04/2019, 25% on 01/04/2020, 25% on 01/04/2021, and 25% on 01/04/2022.
- F2280 shares were acquired under the bluebird bio, Inc. employee stock purchase plan on January 31, 2018.
- F3This option vests over a four-year period, at a rate of twenty-five percent (25%) on January 4, 2019, and in 36 equal monthly installments.